A	B	C
1	Main
2		Brand	NTLA-2002
3		Indication	Hereditary Angioedema: 11k-21.5k in US/EU
4		MOA	kallikrein CRISPR.
5		Administration	IV
6		Clinical Trials
7			Phase I/II HAE - ongoing, presented at ACAAI 2022
8			Phase II component initiates 1H23
9			n=3 25mg - 64% serum kallikrein reduction at week 32, 91% attack rate reduction
10			n=4 50mg - 81% serum kallikrein reduction at day 22
11			n=3 75mg - 92% serum kallikrein reduction at week 16, 78% attack rate reduction